Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Systematic Review of Post-Procedural Rehabilitation Protocols following Percutaneous Needle Tenotomy and Ultrasonic Debridement for Gluteal, Proximal Hamstring, and Patellar Tendinopathy.

American journal of physical medicine & rehabilitation·2026
Same author

An international survey of undergraduate trainees' interests and expected teaching strategies in geriatric oncology.

BMC medical education·2026
Same author

A comprehensive taxonomic checklist of bark and ambrosia beetle species (Curculionidae, Scolytinae).

ZooKeys·2026
Same author

A checklist of South African bark and ambrosia beetles (Coleoptera: Curculionidae: Scolytinae, Platypodinae).

Zootaxa·2025
Same author

Objective risk assessment of bark and ambrosia beetles non-indigenous to North America.

Ecological applications : a publication of the Ecological Society of America·2025
Same author

Current State of Baseball Interval Throwing Programs: A Systematic Review of Content, Structure, and Variability of Published Throwing Programs.

Sports health·2025
Same journal

NPY deficiency protects against osteoporosis by altering bone lipid metabolism.

Prostaglandins & other lipid mediators·2026
Same journal

Beyond association: Mediation roles of lipidomics and cytokine in PCOS uncovered by cross-disciplinary genomics.

Prostaglandins & other lipid mediators·2026
Same journal

Aging induces the hepatic CYP4A-20-HETE axis with stage-dependent oxylipin remodeling.

Prostaglandins & other lipid mediators·2026
Same journal

Impact of COX-2 inhibition by DuP-697 on cyclin B1/Cdc2 dynamics in human medullary thyroid carcinoma cells.

Prostaglandins & other lipid mediators·2026
Same journal

Corrigendum to "Pharmacological modulation of NF-κB-dependent COX-2/PGE₂ signaling influences inflammatory lesion development during Leishmania mexicana infection" [Prostaglandins Other Lipid Mediat. 184 (2026) 107075].

Prostaglandins & other lipid mediators·2026
Same journal

Guggulsterone-mediated selective modulation of nuclear receptors: Implications for FXR-PXR signaling and hepatic metabolic homeostasis.

Prostaglandins & other lipid mediators·2026
See all related articles

Related Experiment Video

Updated: Jun 6, 2026

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry
08:04

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

PGE1 and PGE2 modify platelet function through different prostanoid receptors.

David Iyú1, Madlen Jüttner, Jackie R Glenn

  • 1Cardiovascular Medicine, University of Nottingham, Nottingham, UK. david.iyu@nottingham.ac.uk

Prostaglandins & Other Lipid Mediators
|November 25, 2010
PubMed
Summary
This summary is machine-generated.

Prostaglandin E(1) (PGE(1)) and E(2) (PGE(2)) affect human platelet function through distinct receptor pathways. PGE(2) acts on EP3 and EP4 receptors, while PGE(1) acts on EP3 and IP receptors.

More Related Videos

Prostaglandin Extraction and Analysis in Caenorhabditis elegans
08:50

Prostaglandin Extraction and Analysis in Caenorhabditis elegans

Published on: June 25, 2013

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

Related Experiment Videos

Last Updated: Jun 6, 2026

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry
08:04

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

Prostaglandin Extraction and Analysis in Caenorhabditis elegans
08:50

Prostaglandin Extraction and Analysis in Caenorhabditis elegans

Published on: June 25, 2013

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

Area of Science:

  • Biochemistry
  • Pharmacology
  • Hematology

Background:

  • Prostaglandin E(2) (PGE(2)) influences human platelet function via a balance of EP3 receptor-mediated promotion and EP4 receptor-mediated inhibition.
  • The specific receptors mediating Prostaglandin E(1) (PGE(1)) effects on platelet function remain incompletely defined.

Purpose of the Study:

  • To compare the effects of PGE(1) and PGE(2) on human platelet function.
  • To elucidate the specific prostanoid receptors involved in mediating the actions of PGE(1) and PGE(2) on platelets.

Main Methods:

  • Measurements of platelet aggregation and P-selectin expression induced by the thromboxane A(2) mimetic U46619.
  • Determination of vasodilator-stimulated phosphoprotein (VASP) phosphorylation as a marker of cyclic adenosine monophosphate (cAMP) levels.
  • Utilized selective prostanoid receptor antagonists: CAY10441 (IP), DG-041 (EP3), and ONO-AE3-208 (EP4).

Main Results:

  • Confirmed that PGE(2) interacts with EP3 and EP4 receptors, but not IP receptors, on platelets.
  • Demonstrated that PGE(1) interacts with EP3 and IP receptors, but not EP4 receptors, on platelets.
  • Observed that the net effect of both prostaglandins on platelet function is determined by the balance of opposing signals mediated through different receptors.

Conclusions:

  • PGE(2) and PGE(1) exert differential effects on human platelet function by engaging distinct prostanoid receptor subtypes.
  • The findings clarify the specific receptor interactions for PGE(1) and PGE(2) in regulating platelet activity, highlighting the importance of receptor balance.